Form 4: Xenon CMO Sells Shares After RSU Vesting

Xenon Pharmaceuticals' Chief Medical Officer, Christopher John Kenney, sold 1,410 common shares for tax purposes following the vesting of 3,750 restricted share units.

Summary

• Christopher John Kenney, Chief Medical Officer of Xenon Pharmaceuticals Inc., acquired 3,750 common shares on March 12, 2026, through the vesting of Restricted Share Units (RSUs).
• The RSU award was granted on March 12, 2025, and vests 25% on each of the first four anniversaries of the grant date, with the first vesting occurring on March 12, 2026.
• On March 13, 2026, Mr. Kenney sold 1,410 common shares at a price of $55.225 per share.
• The sale was executed under a Rule 10b5-1 trading arrangement, adopted on December 3, 2025, specifically to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Mr. Kenney directly owns 7,069 common shares and 11,250 Restricted Share Units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, typical for executive compensation and tax planning, with no discernible positive or negative implications for the company's operational or financial performance.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider sales, particularly those executed under a pre-arranged 10b5-1 plan for tax purposes, are common and generally do not signal a change in management's outlook on the company's prospects. This is a routine transaction for executive compensation within the pharmaceutical industry.

Stakeholder Impact

• Shareholders might observe a slight increase in shares available on the market from the sale, but the impact is minimal given the small number of shares relative to the company's total outstanding shares.

Next Steps

• The remaining Restricted Share Units (RSUs) will continue to vest 25% on each of the first four anniversaries of the grant date (March 12, 2025), implying future vesting events on March 12, 2027, March 12, 2028, and March 12, 2029.

Key Dates

Recommendation

This Form 4 details a routine insider transaction involving the vesting of restricted stock units and a subsequent sale to cover tax obligations, executed under a pre-arranged 10b5-1 plan. Such transactions are common for executive compensation and typically do not reflect a change in management's confidence or the company's fundamentals. Therefore, it provides no new information to warrant a change in investment stance, suggesting a "hold" recommendation is appropriate based solely on this filing.

Keywords

Xenon Pharmaceuticals, XENE, insider trading, Form 4, RSU, stock sale, Chief Medical Officer, Christopher John Kenney, 10b5-1 plan